# US 2025/0027087 A1 · Modulating expression of alas1 (5'-aminolevulinate synthase 1) gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0027087 A1
- Document ID: US20250027087A1
- Status: Published application
- Kind: A1
- Application number: 18/778,981
- Filed: 2024-07-21
- Published: 2025-01-23
- Earliest claimed: 2023-07-21
- Assignees: Crispr Therapeutics AG
- Applicants: CRISPR Therapeutics AG
- Inventors: Mary-Lee Dequeant; Heidi Heath; Rachel Yuen
- Web page: https://patentgrep.com/patent/US20250027087A1

## CPC

- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12Y 203/01037: 5-Aminolevulinate synthase (2.3.1.37)
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

The present disclosure relates to methods, compositions and kits for treating conditions that are related to the modulation of expression of 5′-Aminolevulinate Synthase 1 (ALAS1) by gene editing.

## Claims

### Claim 1

A guide RNA (gRNA) for targeting a 5′-Aminolevulinate Synthase 1 (ALAS1) genomic locus, comprising a spacer sequence having 80% sequence identity to any one of the sequences of SEQ ID NOs: 25-48 and 83-112.

### Claim 2 (depends on 1)

The gRNA of claim 1, comprising a spacer sequence comprising any one of the sequences of SEQ ID NOs: 25-48 and 83-112.

### Claim 3 (depends on 1)

The gRNA of claim 1, wherein the gRNA comprises a spacer sequence comprising any one of the sequences of SEQ ID NOs: 25-37 and 100-112.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The gRNA of claim 1, wherein the gRNA is capable of inducing a cutting efficiency of at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% for targeting the ALAS1 genomic locus.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The gRNA of claim 1, wherein the gRNA is a chemically-modified gRNA.

### Claim 9

(canceled)

### Claim 10

A composition, comprising:
(a) a guide RNA (gRNA) that targets a 5′-Aminolevulinate Synthase 1 (ALAS1) genomic locus, or a nucleic acid encoding the gRNA; and
(b) an endonuclease or a nucleic acid encoding an endonuclease.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The composition of claim 10, wherein the gRNA is a chemically-modified gRNA comprising one or more phosphorothioate linkages and/or one or more 2′-O-methyl nucleotides at the 3′ end, the 5′ end, or both.

### Claim 13

(canceled)

### Claim 14 (depends on 10)

The composition of claim 10, wherein the composition comprises (a) the ALAS1 gRNA and (b) the Cas9 endonuclease, and the ALAS1 gRNA and Cas9 endonuclease are formulated as a ribonucleoprotein particle (RNP).

### Claim 15

(canceled)

### Claim 16

A method for treating a disease or disorder caused by 5′-Aminolevulinate Synthase 1 (ALAS1) over-expression in a subject in need thereof, comprising administering to the subject a composition comprising a plurality of nanoparticles complexed with:
(a) a guide RNA (gRNA) that targets a 5′-Aminolevulinate Synthase 1 (ALAS1) genomic locus or a nucleic acid encoding the gRNA; and
(b) a Cas9 endonuclease or a nucleic acid encoding a Cas9 endonuclease, thereby treating the disease or disorder caused by ALAS1 over-expression in the subject.

### Claim 17 (depends on 10, 16)

The method of claim 16, wherein the composition is a composition of claim 10.

### Claim 18 (depends on 17)

The method of claim 17, wherein the gRNA that targets the ALAS1 genomic locus comprises a spacer sequence comprising any one of the sequences of SEQ ID NOs: 25-48 and 83-112.

### Claim 19 (depends on 16)

The method of claim 16, wherein the Cas9 endonuclease is selected from the group consisting of S. pyogenes Cas9, S. aureus Cas9, N. meningitides Cas9, S. thermophilus CRISPR1 Cas9, S. thermophilus CRISPR 3 Cas9, and T. denticola Cas9.

### Claim 20 (depends on 16)

The method of claim 16, wherein the plurality of nanoparticles are lipid nanoparticles comprising one or more neutral lipids, charged lipids, ionizable lipids, steroids, and polymers conjugated lipids.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The method of claim 20, wherein the lipid nanoparticles comprise cholesterol, a polyethylene glycol (PEG) lipid, or both.

### Claim 23 (depends on 16)

The method of claim 16, comprising administering to the subject the composition at a single dose of about 0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1.0 mg/kg, or 2.0 mg/kg of total nucleic acids of (a) and (b).

### Claim 24 (depends on 16)

The method of claim 16, wherein the method comprises a single administration of the composition to the subject.

### Claim 25 (depends on 16)

The method of claim 16, wherein the subject is administered the composition two or more times.

### Claim 26 (depends on 25)

The method of claim 25, wherein each two of the two or more administrations are about two weeks to about four weeks apart.

### Claim 27

(canceled)

### Claim 28 (depends on 16)

The method of claim 16, wherein the expression of ALAS1 in the subject is reduced in the subject; optionally, wherein the expression of ALAS1 is reduced in the liver of the subject; and wherein the reduction is relative to (a) the ALAS1 expression of the subject prior to being administered the composition; (b) the ALAS1 expression in one or more untreated subjects; and/or (c) a reference level of ALAS1 expression of healthy subjects.

### Claim 29 (depends on 28)

The method of claim 28, wherein the expression of ALAS1 in the subject is reduced by at least 20%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 95% after the administration.

### Claim 30

(canceled)
